Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Atlanta Falcons wide receiver Drake London catches a 20-yard touchdown pass from quarterback Michael Penix Jr. "Hey, I’m ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effi ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

What can people eat and drink when taking GLP-1 drugs like Ozempic to help them lose weight? FoodNavigator explores ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Havas launched Shape Shifting — its first-ever creator-led, serialized content platform focused on the unfolding GLP-1 revolution — at the 2025 Consumer Electronics Show (CES). By combining medical ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

People with diabetes who were taking GLP-1 receptor agonist drugs such as tirzepatide and semaglutide had significantly lower rates of hospital readmission, wound re-opening and hematoma after surgery ...

The surging popularity of GLP-1 drugs is beginning to obscure the health consequences if people stop taking them, physicians ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...